Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings

Lau, Hubert D.; Clark, Melissa

doi:10.1002/dc.24539

Cited by 5 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIC is a transcriptional repressor that constitutively represses certain genes targeted for activation by the EGFR/RAS/MAPK pathway. Lau et al[ 7 ] found a CTNNB1 mutation in their analysis of a transformed SCC. In our own analysis, we found that a RNF43 mutation present in the primary adenocarcinoma was lost in the squamous deposit, but otherwise identical.…”

Section: Discussionmentioning

confidence: 99%

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report

Autio

McBride

2022

Journal of Immunotherapy and Precision Oncology

View full text Add to dashboard Cite

Transformation to squamous cell carcinoma (SCC) after initial treatment of a primary prostate adenocarcinoma is rare and typically results in rapid treatment-refractory disease progression and death. Here, we present a case of a 70-year-old man who was initially treated with prostatectomy and radiotherapy, and later developed bone metastases. After commencing systemic therapy with androgen deprivation therapy (ADT) and apalutamide, his prostate-specific antigen (PSA) declined to undetectable levels, yet short-interval imaging demonstrated oligo-progression at T4, with biopsy specimen demonstrating pure SCC. Molecular profiling of both the primary prostate tumor and T4 demonstrated alterations in TMPRSS2-ERG, TP53, and FOXA1 confirming site of origin, with loss of RNF43 in the squamous metastasis. He was treated with stereotactic body radiation therapy to the SCC metastasis and continued on ADT and apalutamide with stable disease for a year post-radiation. This case highlights the importance of imaging to detect non–PSA-producing metastatic disease, the utility of radiation therapy in oligo-progression, and use of molecular profiling to provide insights into the pathogenesis of histologic transformation.

show abstract

Section: Discussionmentioning

confidence: 99%

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report

Autio

McBride

2022

Journal of Immunotherapy and Precision Oncology

View full text Add to dashboard Cite

show abstract

“…Our case ts this situation. Recently, Hubert et al [13] detected a TMPRSS2-ERG fusion, among other genetic alterations, by comprehensive genomic pro ling (CGP), supporting a diagnosis of metastatic SCC transformed from prostatic adenocarcinoma following androgen deprivation therapy (ADT).…”

Section: Discussionmentioning

confidence: 99%

Squamous cell carcinoma transformed from the prostatic adenocarcinoma with endocrine therapy: a case report and literature review

Song¹,

Jiang²,

Hou³

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundSquamous cell carcinoma (SCC) of the prostate is a very rare and highly aggressive tumor, which is insensitive to multiple treatments, prone to metastasis, and has a worse prognosis than adenocarcinoma of the prostate. However, a transformation of prostatic adenocarcinoma into squamous cell carcinoma is rarer and may occur after endocrine or radiotherapy. By now, there are few cases in the world about the transformation from adenocarcinoma into squamous cell carcinoma after treatment. To our knowledge, our case is the first reported in China.Case presentationA 67-year-old man with metastatic adenocarcinoma of the prostate for 2 years, was not suitable for radical prostatectomy due to the disease classified T4N1M1. Endocrine therapy using Luteinizing Hormone-Releasing Hormone (LHRH) analog (leuprorelin) and antiandrogen agent (bicalutamide) was started, and serum prostate-specific antigen (PSA) level gradually decreased to a nadir of 0.04ng/ml. 2 years after treatment, he complained of worsening of lower urinary tract symptoms, and then he underwent transurethral resection of the prostate (TURP). Histopathological examination confirmed most of the tissue areas were accompanied by poorly differentiated keratinizing squamous cell carcinoma. Now, the patient started docetaxel treatment. He has received 2 times of systemic chemotherapy. The patient's current general condition is fair.ConclusionsProstatic adenocarcinoma transformed into squamous cell carcinoma after endocrine therapy is very rare. However, the serum PSA of this tumor is probably normal, PSA and the Gleason grading system are of limited value in the diagnosis of SCC, histopathological can help its diagnosis. The transformation is silent and we cannot know it. The question of whether prostatic adenocarcinoma or SCC of the prostate requires more definitive research to answer.

show abstract

“…This analysis encompasses the examination of tissue architecture, cellular morphology, stromal-epithelial interactions, and the presence of any atypical features. Recent advancements in histopathological techniques, including immunohistochemistry and molecular pathology, have further refined our understanding of prostatic diseases [3].…”

Section: Introductionmentioning

confidence: 99%

Histomorphological Study of Transurethral Resection of Prostate Specimens

SUPARNA V SUVERNAKAR,

DEEPAK SADHU,

NITISH P INGOLE

2024

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: (The objectives of the study are as follows: 1) To study various histomorphological patterns of transurethral resection of prostate specimens. (2) To classify malignant lesions with Gleason’s grading and to do Prostate-specific antigen (PSA) level and immunohistochemistry as required. Methods: It was a cross-sectional study conducted from January 2022 to June 2023 in a tertiary care hospital. Fifty-seven patients study who underwent transurethral resection of the prostate (TURP) surgery with hypertrophied prostate during the study period were included in the study on the basis of a predefined inclusion and exclusion criteria. Demographic characteristics of all the cases were analyzed. Clinical features, presenting complaints, histopathological findings, and the final diagnosis were studied. For statistical purposes, p value < 0.05 was taken as statistically significant. Results: The majority of the participants were in the age group of 60–69 years (42.11%) followed by people in the age group of 70–79 years (35.09%). Benign disease of prostrate was common than the malignant disease. BHP was the most common disease encountered and was seen in 37 (64.91%) cases. Among 37 patients with BHP, 70.27% (26) patients had increased PSA levels. Among 10 patients of BHP with CP 8 (80%) patients had increased levels of PSA. Serum PSA levels were increased in all the cases of malignancy, Adenocarcinoma prostate and PIN. Conclusion: In patients undergoing TURP modified Gleason scoring patterns and prognostic grade grouping should be done in conjunction for assessing prognosis and management. Immunohistochemistry and molecular genetic analysis are valuable adjuncts to the diagnosis in these cases.

show abstract

Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings

Cited by 5 publications

References 24 publications

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report

Squamous cell carcinoma transformed from the prostatic adenocarcinoma with endocrine therapy: a case report and literature review

Histomorphological Study of Transurethral Resection of Prostate Specimens

Contact Info

Product

Resources

About